Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Alzheimer's isn't just a disease of old age. Early-onset AD (before 65) often flies under the radar because memory stays largely intact — instead, it's subtle executive function changes that signal trouble. A newly FDA-cleared blood test, Lumipulse, is now helping clinicians confirm the diagnosis faster and more accurately than ever before.
When we think of Alzheimer's disease (AD), we picture elderly patients struggling with memory. But early-onset AD — diagnosed before age 65 — looks very different. These are working adults who may still remember names and faces but suddenly can't manage finances, learn new tasks, or handle complex decisions. That mismatch between expectation and reality causes significant diagnostic delays, even among experienced clinicians.
The diagnostic landscape is shifting, though. In May 2025, the FDA cleared the Lumipulse G pTau217/β-Amyloid 1–42 Plasma Ratio blood test — the first of its kind to aid in diagnosing AD in adults 55 and older. NYU's Dr. Allison B. Reiss emphasizes that while these biomarker tests are a "revolution," they're not standalone screening tools. They're most valuable when layered on top of full neuropsychological workups — particularly to distinguish early-onset AD from frontotemporal dementia (FTD), a critical distinction since drugs like donepezil can actually worsen FTD.
By the Numbers:
Why it matters: Early-onset AD is underdiagnosed and understudied — younger patients are typically only analyzed as subgroups in larger AD trials. Better diagnostic tools, combined with lifestyle interventions (Mediterranean/MIND diets, exercise, social engagement) and a growing drug pipeline, offer real hope for this often-overlooked population.